October 23, 2026 ·13 min read·中文版

From Fund Exit to Evidence Maturity: Who Takes Drug Development Forward?

A fund can end its investment before the evidence for a drug has matured, but the responsibility for validation remains. A mismatch in horizons raises the weight placed on exitability; whether it also shifts risk elsewhere depends on the continuity of follow-on financing and commitments to validation.

science

1. A fund’s liquidation date and the completion of evidence follow separate clocks

As the generation of candidate molecules accelerates, evidence in humans still requires follow-up. That makes it worth revisiting how financing arrangements affect R&D choices. How much risk of failure a fund can accept and how long it can wait are two different questions.

Risk appetite describes the distribution of losses an investor is willing to bear. The term structure of capital determines when money is committed and when it must be returned. Even when investors recognise the long-term value of a line of research, the manager must arrange investments and exits within the fund’s contractual limits.

EY’s account of institutional venture capital describes a ten-year fund life as a common arrangement, distinguishes the investment period from the subsequent harvesting period, and notes that funds can provide for extensions. This is a description of general VC practice; it cannot be treated as a statistical distribution for funds specialising in biopharma. EY: differences between institutional and corporate VCs[1]

Drug development has no single countdown either. In its 2021 report, the US Congressional Budget Office cites an estimate of about 31 months for preclinical development and 95 months for clinical trials, or roughly 10.5 years in total. The report also presents substantially different results from other samples, so this number cannot stand for every drug’s journey from the discovery of a mechanism to market. CBO: research and development in the pharmaceutical industry[2]

Simply comparing the two averages is still not enough. A fund may invest only once a project reaches the clinical stage, or make an investment late in its own investment period. What matters is whether the remaining fund life at the time of investment can cover the next necessary stretch of evidence generation.

**Concept Evidence maturity**

Efficacy, safety and the associated uncertainties have been sufficiently tested for a specified patient population, indication and regulatory decision. The threshold varies with the decision being made; it does not mean that every unknown has been resolved.

Evidence maturity is not exactly the same as reaching the market. The FDA includes post-market safety monitoring in the drug development process, indicating that questions remain to be answered after regulatory approval. FDA: the drug development process[3]

Figure 1 | Two timelines for a fund and drug development. The markers illustrate one situation in which exit pressure precedes a particular evidence threshold; they do not represent fixed stages or actual durations · Source: drawn by 一目半 (Yimuban); labels translated for this edition

Exit must also be distinguished from failure. A fund may sell its shares while the drug continues in development; a study with a clear negative result may still have completed valuable validation. What needs checking is whether someone remains responsible for the research after the capital exits. The timing of exit alone cannot establish its scientific consequences.

2. Exit pressure enters the choice of projects and milestones in advance

Consider two hypothetical projects with similar expected clinical value. One can produce an interpretable signal in humans relatively quickly; the other requires longer follow-up to determine whether it improves patient outcomes. For a fund with little time remaining, financing and transactions will usually be easier to arrange for the former.

This selection may take place before an investment, or enter the development plan itself: which indication to pursue first, whether to prioritise questions about dose, mechanism or long-term benefit, and what results the next financing round will require. The horizon of capital can therefore affect the ordering of research questions.

This does not mean that short-term endpoints are inherently inferior. A validated surrogate endpoint that reliably predicts clinical benefit can save both time and research resources. The concern is that an indicator capable of quickly generating a transaction signal may receive more weight than its scientific interpretability warrants.

A preference for certain narratives can emerge here. If a fund has a limited window in which to find the next provider of capital, a mechanistic story must do more than explain the biology: it must also let the next investor put a value on the asset. Targets, platforms and clinical signals that can readily be matched to existing transaction benchmarks may gain an extra advantage.

This is a reasoned inference about a mechanism, not yet a measured effect across the industry. If many funds need similar buyers and similar financing windows, the preference may reinforce itself. Even when every fund follows its own risk discipline, capital allocation across projects may still lean towards those for which follow-on financing is easier to obtain.

The crucial distinction comes after exit. An acquisition by a pharmaceutical company, a handover to another fund, or continued financing by a listed company can all keep subsequent validation in private hands. The risk transfer discussed here arises only when commercial financing does not cover the necessary research and public institutions step in, or when research delays add to patients’ burdens.

Figure 2 | When commercial follow-on financing does not cover the necessary validation, the public sector may provide additional research funding, while patients may face extra waiting time and costs. The arrows indicate conditional pathways · Source: drawn by 一目半 (Yimuban); labels translated for this edition

Public research expenditure, patients’ out-of-pocket spending and waiting time are not the same kind of cost. The first concerns who bears the budgetary expense; the other two concern disease burden and lost opportunities. Without an appropriate counterfactual, we cannot attribute all the waiting patients would have experienced anyway to a fund’s exit.

3. Existing research supports horizon effects, but leaves the causal chain incomplete

The evidence on capital horizons is more specific than saying that investors lack patience, and more limited than saying that short-lived funds necessarily harm innovation.

A study published in the Strategic Management Journal in 2022 examined 219 VC-backed US surgical device firms founded between 1989 and 2014. Comparing the timing of exits under different levels of exit pressure and board composition, the authors found that exit pressure was associated with earlier acquisitions and liquidations, but did not significantly change the hazard of an IPO. More independent directors were associated with more favourable exit arrangements. Yao et al.: VC exit pressure and venture exit[4]

This is observational evidence close to the core of the question, and it also supplies a specific limitation: horizon pressure does not affect every exit channel in the same way. The subjects were medical device firms and the main outcomes were corporate exits. The study cannot establish that clinical endpoints in drug development were changed, still less that patients suffered losses.

Another perspective comes from the time clinical research requires.

In their 2015 American Economic Review paper, Budish, Roin and Williams linked cancer clinical trial registrations to patient survival information. Their baseline analysis included 201 cancer type–stage combinations. The main outcome was the number of clinical trials, with comparisons involving patient survival, research sponsors and the conditions under which surrogate endpoints could be used. The authors found evidence that private R&D investment was skewed away from projects with long development times. Budish et al.: do firms underinvest in long-term research?[5]

This was an economic analysis of human study registrations and patient data, not a trial of a drug’s efficacy. It supports the proposition that waiting time affects research allocation, but does not directly test a particular fund’s remaining life.

The paper also discusses short-termism and fixed patent terms: even when capital can wait, longer development may shorten the effective period of exclusivity after launch. Scientific difficulty, market size and the window for commercial returns can all help explain project selection.

The evidence can therefore be separated into two layers. There is already an empirical link between capital horizons and corporate exits. The full chain from fund horizons through clinical choices to public budgets and patient burdens still needs more direct testing.

4. A mega-fund expands risk-bearing capacity without necessarily extending the commitment to validation

Andrew Lo’s mega-fund proposal is useful for separating two questions that are often conflated: how long capital can wait, and how many project failures it can withstand.

In 2012, Jose-Maria Fernandez, Roger Stein and Andrew Lo published a proposal in Nature Biotechnology: bring multiple projects at different stages of development into one entity, combining equity with tranched debt financing. Using historical oncology drug data for simulations, the paper considered funding of $5 billion to $15 billion. It was a modelling study, not a record of actual fund performance. Fernandez et al.: commercialising biomedical research through securitisation[6]

But mega-fund cannot simply be translated as a fund with an exceptionally long life. The stage-specific simulations in the supplementary methods used a fund life of seven and a half years. Early-stage portfolios could sell projects when they entered Phase II; another set of simulations held projects from Phase II through approval. Interim asset sales remained part of the design. Original paper and supplementary methods[7]

This raises a more precise question: whether a portfolio lets capital bear risks it could not otherwise accept is different from whether it commits to completing every project’s full validation.

Extending the horizon and diversifying the assets are two dimensions that can be adjusted separately. The former eases the constraint of having to realise cash by a particular date; the latter reduces the impact of a single project’s failure on the overall pool of capital. Existing VC funds already invest in portfolios. The changes proposed by a mega-fund also involve scale and financing structure, and cannot be reduced to a shift from one project to many.

Figure 3 | One constrained case of concentrated holdings and a short horizon, compared with a design combining diversification and longer holding. The horizon and diversification can be changed separately; the right-hand panel does not represent the specific structure in the original paper · Source: drawn by 一目半 (Yimuban); labels translated for this edition

To assess such an arrangement, we need to keep asking: is funding reserved until critical validation is complete? Does debt repayment depend on selling assets along the way? Who has the right to continue or terminate research after adverse results? If public guarantees are introduced, who ultimately bears the losses?

A larger pool can have greater capacity to bear risk, but it can also have greater liquidity needs. Only the specific repayment terms, governance and research commitments can show which part of the responsibility for validation has changed.

5. Railways and mining show, first of all, that liquidity can be arranged separately

Railways and mining readily bring long construction periods to mind. That does not justify attributing all their historical financing crises to capital horizons that were too short.

Campbell’s study of Britain’s Railway Mania of the 1840s notes that the subscription receipts issued by new railway companies had derivative-like features, allowing investors to take leveraged positions. The useful parallel is this: construction needs continuing investment, while securities can trade before it is complete, and investors’ liquidity arrangements can affect the financing process. Campbell: deriving the Railway Mania[8]

It does not directly establish that fixed fund lives caused the public sector to take over railways before construction was complete. Subscription arrangements, leverage and market expectations are mechanisms that need to be identified separately.

Mining supplies a different reference point. Historical research on Spain’s Río Tinto mines records that a British company acquired perpetual rights to the mines in 1873, then undertook sustained investment in technology and infrastructure. This shows that long-lived assets can be held by a company that continues to operate, without requiring every shareholder to wait until the end of the asset’s life. Boletín Geológico y Minero: technological improvements at the Río Tinto mines[9]

Drug development faces a similar institutional choice: give investors liquidity while preserving continued investment in the project. Share transfers can achieve both, provided that the buyer is willing and able to continue funding the research.

Long-term capital arrangements also exist in biopharma. In its own disclosures, Novo Holdings explicitly connects its evergreen structure with a long-term perspective on life science investing. This is an example of an organisational structure, not sufficient evidence that its clinical decisions are better than those of fixed-life funds. Novo Holdings: Venture Investments[10]

Extension clauses provide a buffer too. But an extension depends on contractual terms and consent procedures; it cannot automatically be equated with covering the full R&D cycle. There are not enough comparable, sector-specific statistics here to support the claim that biopharma funds generally have longer lives or higher rates of extension, so it should not be treated as an established fact.

Long-term arrangements must also address liquidity, constraints on managers and ongoing fees. A liquidation date serves a monitoring function as well. Once it is removed, other mechanisms are needed to constrain inefficient holding and endless follow-on commitments.

6. Identifying horizon distortions requires observing different choices in the face of the same evidence

The strongest counterargument is that early exit may reflect an efficient division of labour. Early investors are good at organising exploration; pharmaceutical companies are good at running large clinical trials. The public sector also has reasons to support research with knowledge spillovers that are independent of private capital’s exit.

Scientific risk is another confounder that cannot be ignored. Development setbacks can simultaneously make financing harder, lengthen holding periods and prompt a sale or termination. Observing that a fund is approaching expiry while a project stalls cannot establish the direction of causation.

A test with greater identifying power would hold the project’s evidentiary state as constant as possible: under the same manager, with similar investment timing and market conditions, compare whether funds with different remaining lives choose different follow-up plans, subsequent commitments and transaction dates when faced with similar projects.

Observing how decisions on the same project change before and after investors with different horizons enter would bring the evidence closer to the core question. It would still require addressing biases such as investors selecting projects and extensions being determined by project quality. Simply comparing average success rates between long- and short-lived funds does little to resolve these issues.

The structure of capital horizons changes how far capital is willing to carry validation. Whether validation risk moves elsewhere depends on whether someone takes on both the financial responsibility and the responsibility for evidence at the point of exit.

Horizons first change the order and boundaries of who bears risk. They may also change total costs by interrupting research, reducing learning or preventing unproductive follow-on investment. Treating the total amount of risk as unchanged is therefore only a starting point for analysis.

Key points

To assess a horizon mismatch, compare the remaining fund life at investment with the time needed for the next necessary stretch of validation, rather than simply comparing average fund and drug development cycles.
Horizons raise the weight placed on exitability. Whether an early exit harms validation requires examining subsequent funding, research responsibility and actual decisions.
Longer holding and portfolio diversification address different constraints. Patient capital must take concrete form in how long funding remains available, repayment arrangements and commitments to validation.

An open question remains for the public sector itself: when it takes over a study requiring years of follow-up, can budget appropriations, project assessments and institutional responsibilities span the same evidentiary horizon? If every funder commits only to reaching the next assessment, changing the source of capital may leave the same validation gap.